Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study

Simple item page
dc.contributor.authorRibaudo, H.
dc.contributor.authorLiu, H.
dc.contributor.authorSchwab, M.
dc.contributor.authorSchaeffeler, E.
dc.contributor.authorEichelbaum, M.
dc.contributor.authorMotsinger-Reif, A.
dc.contributor.authorRitchie, M.
dc.contributor.authorZanger, U.
dc.contributor.authorAcosta, E.
dc.contributor.authorMorse, G.
dc.contributor.authorGulick, R.
dc.contributor.authorRobbins, G.
dc.contributor.authorClifford, D.
dc.contributor.authorHaas, D.
dc.date.issued2010
dc.description.abstractIn AIDS Clinical Trials Group protocols 384, A5095, and A5097s, we characterized relationships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or treatment responses. A stepwise logistic regression procedure selected polymorphisms associated with reduced drug clearance adjusted for body mass index and the composite CYP2B6 516/983 genotype. Relationships between selected polymorphisms and treatment responses were characterized by competing risk methodology. Association analyses involved 821 individuals (317 for pharmacokinetics and 643 for treatment response). Models that included CYP2B6 516/983 genotype best predicted pharmacokinetics. Slow-metabolizer genotypes were associated with increased central nervous system events among white participants and decreased virologic failure among black participants.
dc.description.statementofresponsibilityHeather J. Ribaudo, Huan Liu, Matthias Schwab, Elke Schaeffeler, Michel Eichelbaum, Alison A. Motsinger-Reif, Marylyn D. Ritchie, Ulrich M. Zanger, Edward P. Acosta, Gene D. Morse, Roy M. Gulick, Gregory K. Robbins, David Clifford, and David W. Haas
dc.identifier.citationJournal of Infectious Diseases, 2010; 202(5):717-722
dc.identifier.doi10.1086/655470
dc.identifier.issn0022-1899
dc.identifier.issn1537-6613
dc.identifier.urihttp://hdl.handle.net/2440/63906
dc.language.isoen
dc.publisherUniv Chicago Press
dc.relation.grantRR000095
dc.relation.grantBRS-ACURE-06-00140-T001
dc.relation.grantAI51966
dc.relation.grantRR024996
dc.relation.grantAI062435
dc.rights© 2010 by the Infectious Diseases Society of America
dc.source.urihttps://doi.org/10.1086/655470
dc.subjectHumans
dc.subjectHIV Infections
dc.subjectAlkynes
dc.subjectCyclopropanes
dc.subjectBenzoxazines
dc.subjectAryl Hydrocarbon Hydroxylases
dc.subjectOxidoreductases, N-Demethylating
dc.subjectReverse Transcriptase Inhibitors
dc.subjectAnti-HIV Agents
dc.subjectTreatment Outcome
dc.subjectPharmacogenetics
dc.subjectPolymorphism, Single Nucleotide
dc.subjectFemale
dc.subjectMale
dc.subjectCytochrome P-450 CYP3A
dc.subjectCytochrome P-450 CYP2B6
dc.subjectATP Binding Cassette Transporter, Subfamily B
dc.subjectATP Binding Cassette Transporter, Subfamily B, Member 1
dc.subjectHispanic or Latino
dc.subjectWhite People
dc.subjectBlack People
dc.titleEffect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Pharmacology publications